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Abstract
Background Worldwide, chronic obstructive pulmonary
disease (COPD) is a highly prevalent chronic lung disease
with considerable clinical and socioeconomic impact.
Pharmacologic maintenance drugs (such as bronchodilators
and inhaled corticosteroids) play an important role in the
treatment of COPD. The cost effectiveness of these treat-
ments has been frequently assessed, but studies to date
have largely neglected the impact of treatment sequence
and the exact stage of disease in which the drugs are used
in real life.
Objective We aimed to systematically review recently
published articles that reported the cost effectiveness of
COPD maintenance treatments, with a focus on key find-
ings, quality and methodological issues.
Methods We performed a systematic literature search in
Embase, PubMed, the UK NHS Economic Evaluation
Database (NHS-EED) and EURONHEED (European
Network of Health Economics Evaluation Databases)
and included all relevant articles published between
2011 and 2015 in either Dutch, English or German. Main
study characteristics, methods and outcomes were
extracted and critically assessed. The Quality of Health
Economic Studies (QHES) instrument was used as basis
for quality assessment, but additional items were also
addressed.
Results The search identified 18 recent pharmacoeconomic
analyses of COPD maintenance treatments. Papers reported
the cost effectiveness of long-acting muscarinic antagonist
(LAMA) monotherapy (n = 6), phosphodiesterase (PDE)-
4 inhibitors (n = 4), long-acting beta agonist/inhaled cor-
ticosteroid (LABA/ICS) combinations (n = 4), LABA
monotherapy (n = 2) and LABA/LAMA combinations
(n = 2). All but two studies were funded by the manu-
facturer, and all studies indicated favourable cost effec-
tiveness; however, the number of quality-adjusted life-
years (QALYs) gained was small. Less than half of the
studies reported a COPD-specific outcome in addition to a
generic outcome (mostly QALYs). Exacerbation and
mortality rates were found to be the main drivers of cost
effectiveness. According to the QHES, the quality of the
studies was generally sufficient, but additional assessment
revealed that most studies poorly represented the cost
effectiveness of real-life medication use.
Conclusions The majority of studies showed that phar-
macologic COPD maintenance treatment is cost effective,
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but most studies poorly reflected real-life drug use. Con-
sistent and COPD-specific methodology is recommended.
Key Points for Decision Makers
New pharmacologic treatments for chronic
obstructive pulmonary disease (COPD) indicate
favourable cost effectiveness; however, quality-
adjusted life-year (QALY) gains were small, and less
than half of the studies included a COPD-specific
outcome.
Exacerbation and mortality rates were the main
drivers of cost effectiveness.
According to the Quality of Health Economic
Studies (QHES), the quality of the studies was
generally sufficient, but most studies poorly reflected
cost effectiveness in real life.
1 Introduction
Chronic obstructive pulmonary disease (COPD) is a pro-
gressive lung disease characterized by reduced airflow and
increased chronic inflammatory response in the airways
due to noxious particles and gasses [1]. COPD is mostly
diagnosed in people aged C40 years. In recent years, its
prevalence is more equally distributed between men and
women due to a more equal distribution of smoking, as
well as outdoor and indoor air pollution [1]. Symptoms of
COPD include breathlessness, excessive sputum produc-
tion, and chronic cough [1]. Exacerbations and comor-
bidities contribute to the impact of COPD on patients’
quality of life [1]. Therefore, the management of exacer-
bations and comorbidities is key in the treatment of COPD
to prevent further progression [1].
COPD is diagnosed by symptoms and airflow obstruc-
tion assessed via forced expiratory volume in 1 second
(FEV1) divided by the forced vital capacity (FVC)\70 %.
FEV1 is measured using spirometry and is expressed as a
percentage of the expected value. Historically, the severity
of COPD was merely defined by lung function variables
such as the FEV1. Severity grades included Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD) 1
(FEV1 %predicted [80), GOLD 2 (FEV1 %predicted
50–80), GOLD 3 (FEV1 %predicted 30–50) and GOLD 4
(FEV1 %predicted\30). Since 2011, the severity of COPD
has been defined based on a combined assessment of lung
function, symptoms and future risk of exacerbations and is
classified as GOLD A, B, C and D [2]. GOLD A is the least
severe stage, and GOLD D is the most severe stage of
COPD with the worst lung function, highest exacerbation
risk and most symptoms. Recent studies have shown that
the new GOLD classification was more strongly related to
clinical outcomes, quality of life and costs than the old
GOLD classification [3, 4].
Various forms of pharmacological and non-pharmaco-
logical treatments are available to decrease symptoms,
prevent exacerbations and increase the quality of life of
patients with COPD. Non-pharmacological treatments
include smoking cessation, exercise, nutrition and pul-
monary rehabilitation. The cornerstone pharmacological
maintenance treatment consists of the group of bron-
chodilators: long-acting beta2 agonists (LABA) and long-
acting muscarinic antagonists (LAMA). Other pharmaco-
logical maintenance treatments include methylxanthines,
inhaled corticosteroids (ICS), systemic corticosteroids and
phosphodiesterase (PDE)-4 inhibitors. Short-acting beta-
agonists and short-acting muscarinic antagonists are pri-
marily used for rapid symptom relief. The GOLD guide-
lines recommend use of a short-acting bronchodilator for
GOLD A, a LABA or LAMA for GOLD B, an
ICS ? LABA or LAMA for GOLD C and ICS ? LABA
and/or LAMA for GOLD D. In daily clinical practice, the
use of a combination of multiple COPD drugs appears to be
increasing [5].
Several novel pharmacotherapies have recently entered
the market, such as new long-acting bronchodilators for
once-daily dosing (indacaterol, olodaterol), new LAMAs
(glycopyrronium, aclidinium), fixed-dose LAMA/LABA
combinations (tiotropium/olodaterol, aclidinium/for-
moterol, umeclidinium/vilanterol, glycopyrronium/inda-
caterol) and a new fixed-dose combination of LABA/ICS
(vilanterol/fluticasone furoate). Many of these novel ther-
apies focus on improving dosing convenience. There is also
evidence of synergistic effects, but these are not fully
additive [6]. When the law of diminishing returns applies,
it may become increasingly difficult to demonstrate that the
combination therapies are cost effective, especially since
some of the commonly used drugs have gone, or will soon
go, out of patent and thus become relatively cheap.
Cost-effectiveness analyses (CEAs) help to provide
insight in the balance between incremental costs and
incremental effects of a new treatment compared with
current standards of care. In 2012, Rutten-van Mo¨lken and
Goossens [7] systematically reviewed the cost effective-
ness of pharmacological maintenance treatment for COPD.
They highlighted that ‘‘it is important that future studies
improve consistency of study methodology and choice of
comparators in order to enable meaningful comparison of
study results and that it is necessary that more and longer
trial-based cost-effectiveness studies are conducted’’. The
recommendation regarding the application of consistent
methodology was in line with an earlier review from 2008
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[8]. Given the recent market entry of several new COPD
treatments, an update of the previous reviews is required.
The aim of this paper is to systematically identify the
recent literature regarding the cost effectiveness of phar-
macological maintenance treatments for COPD, review the
quality of the studies and report on their strengths and
limitations. We also describe current methodological
trends, summarise the main drivers of favourable cost
effectiveness of COPD treatment and specifically relate our
findings to the conclusions from the previous review [7].
2 Methods
2.1 Search Strategy
The search strategy used to perform the literature search for
economic evaluations of COPD treatment was based on the
strategy of the previous review from 2012 [7]. In short, we
performed a systematic literature search in Embase,
PubMed, the UK NHS Economic Evaluation Database
(NHS-EED) and EURONHEED (European Network of
Health Economics Evaluation Databases). We included all
relevant papers published between 1 November 2011 (end
date of the previous search) and 31 December 2015.
The search strategies in the individual databases were as
follows.
• Embase: ‘chronic obstructive pulmonary disease’/exp
AND ‘cost effectiveness’/exp AND [article]/lim AND
([dutch]/lim OR [english]/lim OR [german]/lim) AND
[humans]/lim.
• PubMed: ((Chronic[All Fields] AND (‘‘lung’’[MeSH
Terms] OR ‘‘lung’’[All Fields] OR ‘‘pulmonary’’[All
Fields]) AND obstructive[All Fields] AND (‘‘dis-
ease’’[MeSH Terms] OR ‘‘disease’’[All Fields])) AND
(‘‘cost-benefit analysis’’[MeSH Terms] OR (‘‘cost-ben-
efit’’[All Fields] AND ‘‘analysis’’[All Fields]) OR
‘‘cost-benefit analysis’’[All Fields] OR (‘‘cost’’[All
Fields] AND ‘‘effectiveness’’[All Fields]) OR ‘‘cost
effectiveness’’[All Fields])) AND (‘‘2011/11/
01’’[PDAT]: ‘‘3000’’[PDAT]).
• UK NHS: ‘chronic obstructive pulmonary disease’ and
‘pharm*’ and ‘economic evaluation’.
• EURONHEED: ‘treatment’ as the type of intervention,
‘respiratory tract diseases’ as disease and ‘drug’ as
keyword.
The titles and abstracts were screened by SvdS and
checked by JvB. Based on titles and abstracts, we assessed
whether the studies met the following inclusion criteria:
• Full text available;
• In English, Dutch or German;
• An identifiable group of COPD patients;
• Only original research, no review papers;
• Full economic evaluations, including costs and effects;
• Only maintenance treatment drugs; no drugs used for
acute exacerbations, no alfa-antitrypsin replacement
therapy, no vaccination strategy or non-pharmacolog-
ical treatments.
Papers that seemed to meet these criteria based on title
and abstract were further assessed in more detail by two
independent reviewers (SvdS and JvB). Discrepancies were
solved by consensus. The reference lists of these papers
were also assessed to identify more papers that might meet
the criteria above. The systematic review followed the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [9].
2.2 Data Extraction
The data extracted from the papers included the following
main study characteristics, reported by the class of drug
assessed (LAMA, LABA, PDE-4 inhibitors, LABA/ICS
and LABA/LAMA): first author, year, country, funding,
drug therapy described and the comparator(s), difference in
costs, difference in outcomes (quality-adjusted life-years
[QALYs] gained, life-years [LYs] gained, exacerbation
risk or pneumonia risk), incremental cost-effectiveness
ratio (ICER), and authors’ conclusions. Other data extrac-
ted concerned the study design, time horizon, sensitivity
analyses and perspective. The study perspective was
described as either societal (including all relevant actual
costs, inside and outside the healthcare sector) or health-
care payer (including only healthcare costs). The latter
could use either actual costs of resources used or tariffs
paid). Data extraction was performed by one author (SvdS)
and checked by another author (JvB).
2.3 Evidence Summary
Following the narrative description of the studies per drug
class, we provide a summary of the evidence. This sum-
mary is based on both the evidence from the studies in this
review and the studies included in the previous review [7].
Evidence could either be ‘strong’ (five or more studies with
consistent results), ‘moderate’ (three to four studies with
consistent results), ‘limited’ (fewer than three studies with
consistent results) or ‘inconclusive’ (contrasting results no
matter the amount of studies).
2.4 Quality Assessment
We considered the following checklists for systematic
assessment of the quality of the papers: the Phillips
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checklist, the Quality of Health Economic Studies
(QHES) checklist and the Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) checklist
[10–12]. The Phillips checklist was excluded as it is pri-
marily useful for the quality assessment of modelling
studies. Although the majority of articles included were
modelling studies, we preferred consistency across all
articles, including non-modelling studies. The CHEERS
checklist was excluded as it did not provide an average
quality score. We eventually chose the QHES checklist
because it provides a quantitative score. The quality
assessment was performed by two independent reviewers
(SvdS and other randomly chosen authors). If the results
differed between reviewers, consensus was reached
through discussion. Four QHES-based quality levels have
been established in previous assessments: category 1
(0–25.0 points), category 2 (25.1–50.0 points), category 3
(50.1–75.0 points) and category 4 (75.1–100 points) [13].
2.5 Critical Assessment of Methods and Outcomes
As the QHES does not cover all topics and is not
specifically designed for COPD cost-effectiveness studies,
the following additional issues regarding methods and
outcomes were further explored and discussed in detail:
(1) study design, (2) time horizon, (3) variation in mod-
elling approach (including cycle length and model states),
(4) variation in outcomes, (5) variation in costs, (6)
variation in analytical approach, (7) transferability issues
and (8) other issues. Most of these issues were identified
in the previous review [7] and are revisited to assess the
current state of the art.
3 Results
3.1 Search Results
The literature search resulted in 210 hits. After reviewing
titles and abstracts, 39 papers were included for full-text
review. Subsequently, 18 papers complied with the inclu-
sion criteria. Figure 1 is a flow diagram showing the
inclusion and exclusion of papers at various stages of the
process.
3.2 Main Study Characteristics
Sections 3.2.1–3.2.5 detail the main study characteristics
and brief descriptions of the economic evaluations of
LAMA, LABA, PDE-4 inhibitors, LABA/ICS and LABA/
LAMA therapies. Tables 1, 2, 3, 4 and 5 provide overviews
of the study characteristics, by drug class.
3.2.1 Long-Acting Muscarinic Antagonist (LAMA)
Monotherapy
LAMAs are a mainstay therapy for patients with GOLD B,
C or D COPD [1]. In the previous review, 11 studies
assessed the cost effectiveness of tiotropium, the sole
LAMA available at that time, compared with usual care
(placebo, ipratropium or salmeterol); most studies indicated
favourable cost effectiveness [7]. In the current review, six
new articles reported the cost effectiveness of LAMAs
(Table 1). Two of the studies were conducted in Sweden;
the others were conducted in the USA, Italy, the UK and
Belgium, and Germany. The LAMAs assessed were tio-
tropium, glycopyrronium and aclidinium. All studies were
funded by a pharmaceutical company, combined clinical
trial efficacy data with modelling and included QALYs as an
effectiveness outcome. Four studies compared tiotropium
versus either glycopyrronium, (as an addition to) usual care
or versus salmeterol (Table 1). Three of four studies used
the UPLIFT clinical trial data, often combined with data
from other trials or observational data sources [14–16]. In
these three UPLIFT-based studies, tiotropium was deemed
cost effective compared with usual care (i.e. all respiratory
medication except anticholinergic drugs) with ICERs rang-
ing between €8000 and €24,000 per QALY over 4-year [16]
and lifetime time horizons [14, 15]. All indicated high
probabilities (60–90 %) of being cost effective at current
willingness-to-pay (WTP) thresholds used in the respective
countries. Note that in two of these three studies, QALY
differences were\0.10 per patient [15, 16]. The remaining
study reported higher QALY gains (0.42) [14]; however, the
authors assumed an additional positive effect of tiotropium
on cardiovascular outcomes (myocardial infarction, con-
gestive heart failure) and used mapping to convert St
George’s Respiratory Questionnaire (SGRQ) scores into
utilities. One study compared tiotropium versus salmeterol
based on the head-to-head POET-COPD clinical trial [17].
In this economic evaluation, 1-year trial-based cost effec-
tiveness as well as model-based cost-effectiveness estimates
(over 1-year and 5-year time horizons) were reported from
both the societal and the payer’s perspective. The 1-year
model-based ICERs fell in the same range as those from the
studies that compared tiotropium versus usual care (that may
have included salmeterol), while the 5-year ICER was
slightly lower when calculated from the payer’s perspective.
At a WTP of €20,000 per QALY (payer’s perspective), the
probability of tiotropium being cost effective was 62.5 %.
The trial-based economic endpoint was COPD specific:
€2000 (PP) or €2600 (societal perspective) per exacerbation
avoided. Note that this is lower than the €4200 per exacer-
bation avoided reported by Zaniolo et al. [14], whereas the
costs per QALY were slightly higher.
46 S. van der Schans et al.
The two remaining studies in this category assessed
glycopyrronium and aclidinium, and both studies took
tiotropium as comparator. A Swedish study, based on the
1-year head-to-head GLOW-2 trial that included patients
with moderate to very severe COPD, concluded that gly-
copyrronium was cost saving with a 99 % probability of
dominance. Their conclusions were based on very small
QALY gains (0.005) combined with cost savings over a
3-year time horizon from a societal perspective [18]. This
contrasts with another Swedish study discussed in the
previous paragraph, which found the opposite QALY gain
(i.e. more QALYs for tiotropium) when comparing tio-
tropium and glycopyrronium [15]. Drug costs and severe
exacerbation costs were in the same range, but the latter
study took a payer’s perspective and based its efficacy
measures on the SPARK trial, which included patients with
severe or very severe COPD with at least one exacerbation
in the previous year. Another study evaluated the cost
effectiveness of aclidinium as an alternative to tiotropium
in the USA over a 5-year time horizon [19]. The authors
concluded that aclidinium was potentially cost effective
(probability of dominance: 84 %), but QALY gains were
marginal (0.0044) and total costs did not differ signifi-
cantly. Given the lack of any long-term head-to-head trials
comparing aclidinium versus tiotropium, the authors used a
network meta-analysis (NMA) based on a set of different
data sources and assumptions. However, as the authors did
not clearly describe the limitations of this NMA, conclu-
sions are therefore very tentative.
Considering the large number of past and current studies
with mostly consistent results, there is strong evidence that
tiotropium monotherapy is cost effective compared with
usual (non-LAMA) care. However, evidence regarding the
relative cost effectiveness of tiotropium, glycopyrronium
and aclidinium versus each other is inconclusive.
3.2.2 Long-Acting Beta2 Agonist (LABA) Monotherapy
LABAs are a mainstay therapy for patients with GOLD B,
C or D COPD [1]. In the previous review, 13 studies
assessed the cost effectiveness of LABAs versus usual care
(ipratropium) or placebo: 11 studies reported on salmeterol,
one on formoterol, one on LABAs in general, and most
studies indicated favourable cost effectiveness [7]. The
present review identified two new studies [20, 21], which
were both manufacturer-sponsored studies by the same first
author that compared the cost effectiveness of once-daily
indacaterol versus once-daily tiotropium and twice-daily
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salmeterol in the UK and in Germany [20, 21]. Both studies
included patients with moderate to very severe COPD and
followed them for 3 years using the same Markov model.
The model results were compared with other (unspecified)
studies and national mortality statistics and were reviewed
by an external health economist. Efficacy measures were
taken from the 26-week INHANCE and INLIGHT-2 trials
[20, 21]. In the UK and Germany, indacaterol 150 lg was
found to dominate both tiotropium and salmeterol. In the
UK, the QALYs gained for indacaterol versus tiotropium
were relatively small, ranging from 0.008 (dose 150 lg) to
0.011 (dose 300 lg); the number of QALYs gained versus
salmeterol were similar, as were the German results. The
model was sensitive to changes in mortality estimates, the
severity of the disease of the patient population and the
time horizon. For the UK, the authors concluded that both
doses of indacaterol (150 and 300 lg) were dominant. The
probabilistic sensitivity analysis (PSA) showed that 72 %
(vs. salmeterol) and 89 % (vs. tiotropium) of the iterations
indicated dominance for indacaterol. In Germany, only the
150-lg dose was dominant (with dominance probabilities
of 78 % vs. salmeterol and 90 % vs. tiotropium), and the
more expensive dose (indacaterol 300 lg) was deemed cost
effective (€28,301 per QALY). It seems that the difference
between countries arises from differences in drug costs. In
Germany, the 300-lg dose was 1.5 times more expensive
than the 150-lg dose, whereas in the UK, both doses were
equally priced. The costs of the comparator drugs also
varied.
Based on results from over ten studies included in the
previous review, evidence is strong that LABAs (particu-
larly salmeterol) are cost effective compared with iprat-
ropium, which was usual care at that time. Given that the
cost effectiveness of indacaterol has only been assessed in
two studies, the evidence that indacaterol is cost effective
over tiotropium or salmeterol (currently considered usual
care) is limited.
3.2.3 Phosphodiesterase (PDE)-4 Inhibitors
Roflumilast is indicated as an add-on to bronchodilators for
patients with GOLD C or D COPD associated with chronic
bronchitis [1]. The previous review included one study on
roflumilast, which was only deemed cost effective in a
subgroup with very severe COPD [7]. Four new studies
reported the cost effectiveness of PDE-4 inhibitors (roflu-
milast) when added to LABA, LAMA, LABA/ICS or a
combination of these therapies (LABA/ICS ? LAMA)
compared with the therapy without a PDE-4 inhibitor
(Table 3). The studies were conducted in Switzerland (one
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CUA cost-utility analysis, ICER incremental cost-effectiveness ratio, LYs life-years, QALYs quality-adjusted life-years, SA sensitivity analysis
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study), Germany (one study) and the UK (two studies).
They were all manufacturer funded and used a combina-
tion of clinical trial data and lifetime modelling. Effects
measures were all based on a relative ratio of exacerbation
rate (RRR) of around 0.80 for adding roflumilast (Sup-
plementary Appendix Table A3).
Two studies [22, 23] assessed the addition of roflumilast
to LABA monotherapy using a similar Markov model and
basing their main efficacy measure on a pooled analysis of
the 52-week M2-124 and M2-125 trials [24]. These trials
included patients with severe to very severe COPD,
bronchitis symptoms and a history of exacerbations. In the
UK, Samyshkin et al. [23] showed that the addition of
roflumilast to LABA monotherapy resulted in a gain of
0.16 QALYs and an ICER of around £19,500 per QALY.
The PSA indicated a probability of 82 % of being cost
effective at a WTP of £30,000 per QALY. In Germany,
0.234 QALYs were gained at slightly higher costs,
resulting in a similar ICER of €19,457 per QALY gained.
The PSA showed that over 80 % of the iterations were
below a WTP of €30,000 per QALY. Nowak et al. [22]
also reported the prevention of 2.4 exacerbations over a
lifetime (€1852 per exacerbation avoided). Both studies
concluded that adding roflumilast to long-acting bron-
chodilators can be cost effective in patients with severe to
very severe COPD with chronic bronchitis and a history of
exacerbations.
The other two studies [25, 26] were based on efficacy
measures obtained from a published mixed-treatment
comparison of trials ranging from 24 weeks to 4 years.
When adding roflumilast to, respectively, LAMA, LABA/
ICS or LAMA ? LABA/ICS in Switzerland, all additions
were cost effective, with ICERs around €10,000 per QALY
(Table 3) with probabilities of 79, 96 and 96 %, respec-
tively, of being cost effective at a €60,000 per QALY
threshold. Hertel et al. [26] reported on the addition of
roflumilast to LABA/ICS in the UK and reported ICERs of
around €19,000 per QALY gained (€16,000 per QALY
gained for ICS-intolerant patients), also with a [80 %
probability of being cost effective at a threshold of £30,000
per QALY. The higher UK ICER may be partly explained
by differences in healthcare systems, but is more likely to
be because of higher relative drug costs for the addition of
roflumilast in the UK (1.52 times usual care in the UK vs.
1.28 times in the Switzerland). The addition of roflumilast
to current maintenance treatment was considered cost
effective in both cases for patients with severe to very
severe COPD who continue to experience exacerbations
despite treatment with bronchodilators.
Based on these four studies and the previous review [7],
evidence is strong that add-on therapy with roflumilast is
cost effective when used in a specific subgroup: patients






































































































































































































































































































































































































































































































































































































































































































































































































































































































52 S. van der Schans et al.
exacerbations, bronchitis symptoms and not controlled
with bronchodilators alone.
3.2.4 LABA/Inhaled Corticosteroid (ICS) Combination
Therapy
LABA/ICS are indicated for patients with COPD with a
FEV1 % predicted \50 and frequent exacerbations (i.e.
GOLD C and D). This combination is proven to be more
effective than LABA or ICS alone and improves health
status and number of exacerbations; however, it is also
associated with an increase in pneumonia risk [1]. The
previous review included 12 studies on the cost effectiveness
of LABA/ICS; however, populations, comparators and
ICERs varied widely [7]. The four new studies reporting on
LABA/ICS combination therapies included papers on sal-
meterol/fluticasone, formoterol/budesonide and formoterol/
fluticasone (Table 4). The studies, including two that were
not industry funded, used very different methods, contrast-
ing with the frequently used Markov models in other drug
categories. The first non-industry-funded study was a CEA
performed alongside a 6-month prospective observational
study in a tertiary care hospital in South India [27]. It
included a small cohort (n = 90) of patients with severe and
very severe COPD irrespective of their history of exacer-
bations. Salmeterol/fluticasone, formoterol/budesonide and
formoterol/fluticasone were compared in this cohort, but
details on the methods and results were limited, and dif-
ferences in exacerbations and costs seemed non-significant.
The authors concluded that all LABA/ICS had favourable
therapeutic performance, but salmeterol/fluticasone and
formoterol/budesonide were deemed most effective based
on lung function improvement. The second non-industry-
funded study was a mathematical modelling exercise that
assessed six different hypothetical treatment scenarios,
including LABA/ICS for patients with GOLD 3/4 disease,
for the African and Asian sub-regions [28]. It was concluded
that this therapy was cost effective compared with no
treatment in both the African sub-region and the Asian sub-
region. Notably, this was the only study that used disability-
adjusted LYs (DALYs) as an outcome measure.
The other two studies both evaluated formoterol/
budesonide and were sponsored by the manufacturer. The
first study assessed the costs and outcomes compared with
salmeterol/fluticasone using Swedish real-world effective-
ness data from the observational PATHOS study combined
with Italian cost data [29]. It showed cost savings mainly
driven by lower drug costs and fewer COPD- and pneu-
monia-related hospitalizations. This was one of the few
studies that lacked a PSA. The other economic evaluation
was performed alongside the 12-week CLIMB trial and
combined its international resource use data with Scandi-
navian cost data to estimate the cost effectiveness of adding
budesonide/formoterol to tiotropium in patients with
moderate to very severe COPD and a history of exacer-
bations [30]. Several scenarios were assessed, but all
ICERs were\€350 per exacerbation avoided and, in some
cases, the addition was even dominant.
The results of the LABA/ICS evaluations included in the
previous review showed contrasting results with a wide
variation in ICERs [7]. The four new studies in this review
had considerable limitations: a small cohort and an inap-
propriate population [27], no usual care control group [28],
a combination of data from two different countries [29] and
limited follow-up [30]. Therefore, the evidence regarding
the cost effectiveness of LABA/ICS in patients with COPD
is inconclusive. Targeting LABA/ICS to the correct COPD
population (i.e. GOLD C and D) may result in more
favourable cost effectiveness.
3.2.5 LABA/LAMA Combination Therapy
LABA/LAMA combination therapy is indicated for
patients with COPD not controlled with a single long-act-
ing bronchodilator alone (i.e. GOLD B, C or D) [1]. In the
previous review, one study assessed the cost effectiveness
of the combination of tiotropium and salmeterol in two
separate inhalers versus tiotropium alone and found that the
combination was dominated by tiotropium alone [7]. Two
studies assessed ‘triple therapy’, consisting of a combina-
tion of separate LAMA and LABA/ICS, but reported
mixed cost-effectiveness results [7]. This review included
two new studies [31, 32], both funded by the manufacturer,
that reported the cost effectiveness of LABA/LAMA fixed-
dose combination (FDC) therapy in Sweden and the UK
(Table 5). In Sweden, the once-daily LABA/LAMA com-
bination indacaterol/glycopyrronium (FDC in one inhaler)
was compared with indacaterol ? glycopyrronium (two
separate inhalers) in a cost-minimization analysis [31].
Cost effectiveness compared with salmeterol/fluticasone
was also assessed. Both analyses were performed in a
population with moderate to severe COPD and a low
exacerbation risk. Note that salmeterol/fluticasone is not
indicated for patients with COPD with low exacerbation
risk and thus cannot be considered a suitable comparator.
Clinical efficacy data from four different trials were used
(Supplementary Appendix Table A3). Patients were fol-
lowed over a lifetime horizon using a validated patient-
level simulation model that used age, sex, height, smoking
status and starting FEV1 level as input. Compared with its
free combination, indacaterol/glycopyrronium FDC resul-
ted in cost savings ranging from Swedish krona (SEK) -
768 (1 year) to SEK -8703 (lifetime) depending on the
time horizon. The cost difference was mainly driven by
higher drug costs for the separate inhaler therapy. Com-
pared with salmeterol/fluticasone, FDC showed an
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incremental gain in QALYs of 0.001 (1-year time horizon)
to 0.200 (lifetime) at lower costs (SEK -43,033). There-
fore, indacaterol/glycopyrronium FDC was deemed domi-
nant. Indacaterol/glycopyrronium FDC remained dominant
in all iterations of the PSA. In clinical terms, indacaterol/
glycopyrronium resulted in the avoidance of 1.07 exacer-
bations and a reduction of 0.31 pneumonia events over a
lifetime horizon.
The second study compared umeclidinium/vilanterol
combination therapy versus tiotropium monotherapy over a
lifetime horizon in the UK [32]. The COPD population
assessedwas supposed to be symptomatic (modifiedMedical
Research Council [mMRC] scale scoreC2). This study used
a linked-equations disease model based on the ECLIPSE
study [33] and included the input parameters age, sex, body
mass index, cardiovascular and other comorbidities, exac-
erbation history, smoking status, health status (SGRQ), lung
function, dyspnoea and 6-minute walking test result. Utility
was derived from the SGRQ score using a mapping model.
Treatment effects were based on a meta-analysis of FEV1
data at 24 weeks from three clinical trials and resulted in an
increase of 0.18QALYs, 0.36 LYs and an ICER of £2088 per
QALY, assuming a price equal to that of tiotropium. The
probability of being cost effective at a threshold of £20,000
per QALY was over 90 %.
As only two studies assessed the cost effectiveness of
two different LABA/LAMA combinations, and the studies
in the previous review showed mixed results [7], the evi-
dence that LABA/LAMAs are cost effective over tio-
tropium or other comparators is considered inconclusive.
3.2.6 Main Drivers of Cost Effectiveness of Chronic
Obstructive Pulmonary Disease (COPD) Treatment
In 12 of the 18 articles, the main drivers of cost effectiveness
were presented in a tornado diagram or table. In most cases,
the relative risk of exacerbations and the mortality rate were
the main drivers of cost effectiveness. The choice of the time
horizon also had a strong impact on the model estimates.
Notably, for some therapies (such as roflumilast and ICS),
the baseline exacerbation rate of the target population seems
to be a prerequisite for favourable cost effectiveness. Other
factors that had considerable influence on cost-effectiveness
estimates were hospitalization rates, either with a general
cause or due to exacerbations or pneumonia.
3.3 Quality Assessment Results
We assessed the quality of the studies using the QHES
checklist (Fig. 2). Total scores per study are provided in
Tables 1, 2, 3, 4 and 5 and detailed scores in Supplementary
Appendix Table A1. Based on QHES total score alone, 14 of
the 18 studies scored in category 4 (highest category), two in
category 3, one in category 2 and one in category 1 (lowest
category). Performance in terms of the discussion of
potential bias (item 14) was relatively low in all studies.
3.3.1 Choice of Economic Model (Objective, Perspective,
Structure and Time Horizon)
Of the 18 cost-effectiveness studies included in this review,
12 were cost-utility analyses (CUAs), five were CEAs and
one used both CEA and cost-minimization analyses
(Tables 1, 2, 3, 4, 5). All studies stated their objective in a
clear, specific and measurable manner (QHES item 1), and
17 stated their perspective (QHES item 2). Reasons were not
always explicitly stated, but the perspectives did not differ
from their country’s recommendations or at least also
included the recommended perspective [34]; 15 took a
healthcare payer perspective (Supplementary Appendix
Table A2). Four of these also applied a societal perspective
[17, 18, 27, 30], two only used the societal perspective
[15, 31] and another did not explicitly mention the per-
spective, but it seemed to have been undertaken from a
healthcare perspective [28]. A total of 15 studies were
modelling studies; the remaining three were performed
alongside a clinical trial or used observational data, and all
but two studies used efficacy data for their main effect esti-
mate (QHES item 3). Follow-up of the efficacy trials varied
between 12 weeks and 4 years (Supplementary Appendix
Table A3). The time horizons (QHES item 8) differed con-
siderably between the studies (Tables 1, 2, 3, 4, 5). For
analyses conducted alongside clinical trials, the time hori-
zons were 3 and 6 months [27, 30]. Time horizons in the
modelling studies ranged from 1 year to lifetime, and cycle
length varied between 1 month and 1 year (Supplementary
Appendix Table A2). In general, the structure and health
states of the model studies sufficiently reflected the natural
development and progression of COPD (Supplementary
AppendixTableA2). TheCEAs in this studywere conducted
in 15 countries/regions. Not all countries recommended a
specific time horizon for CEAs; in those that did, recom-
mendations were generic, i.e. that all relevant health effects
and cost consequences should be covered [34]. Considering
these recommendations, the time horizons of the included
studies in our review were mostly appropriate; however, 3
and 6 months may be considered too short as these time-
frames do not account for the seasonality of COPD [35].
3.3.2 COPD Model Inputs: Costs and Effectiveness
Measures
A total of 15 studies stated the methodology for data
abstraction (QHES item 7). The measurement of costs
(QHES item 9) and outcomes (QHES item 10) was clearly
described in 16 and 14 studies, respectively
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(Supplementary Appendix Table A1). In most studies, the
number of exacerbations or the exacerbation risk/rate was
the main cost driver. Most articles differentiated between
severe, moderate and/or mild exacerbations, and the costs
of treatment for severe versus moderate/mild exacerbations
varied widely, ranging between 4.14 times [15] and 21.46
times higher [31]. Only two articles differentiated between
the costs of exacerbation within different disease severity
stages of COPD [14, 15]. Multiple outcomes were used to
describe the effectiveness of the studied therapy (Tables 1,
2, 3, 4, 5); 17 studies reported an ICER, and the most
frequently included effectiveness outcome was the number
of QALYs gained (14 of 18). The majority of articles used
the EuroQoL 5-Dimension (EQ-5D) questionnaire to cal-
culate the utility used to estimate QALY gains, which were
\0.30 in all cases in which QALYs were directly esti-
mated. QALY gains ranged from 0.0044 for aclidinium (vs.
tiotropium) over a 5-year time horizon [19] to 0.289 for
roflumilast (as add on to LABA/ICS) over a lifetime
horizon [25]. Two studies used a mapping model for the
translation of the SGRQ score into QALYs. The QALY
gains in those studies were 0.18 and 0.42 over a lifetime
horizon [14, 32]. The slightly higher QALY gains may be
due to the mapping; however, these two studies also
included the impact on (non-respiratory) comorbidities that
may have resulted in higher QALY gains. Nine studies also
reported the number of LYs gained as an outcome. Other
frequently used outcomes were the number of exacerba-
tions (7 of 18), improvement in FEV1 (3 of 18) or change in
exacerbation risk (3 of 18). One study used DALYs to
describe effectiveness [28], and two studies included the
improvement in pneumonia risk [29].
3.3.3 Model Uncertainty, Validation and Limitations
All but one study included some sort of sensitivity analysis
(Supplementary Appendix Table A2): two performed uni-
variate sensitivity analyses only, one performed PSA only,
and 11 included both univariate analyses and PSA. Six
studies also performed one or multiple scenario analyses
(QHES item 5). The potential for bias was poorly reported
in the vast majority of studies (QHES item 14). Most
modelling studies mentioned that the core Markov
assumption that a cohort’s future progression is dependent
only on their current state of health was a limitation (QHES
item 13). Whilst this assumption may not hold true when
Fig. 2 Percentage of maximum Quality of Health Economic Studies
(QHES) score per question across the total of studies. Q1: Was the
study objective presented in a clear, specific, and measurable
manner?; Q2: Were the perspective of the analysis (societal, third-
party payer, etc.) and reasons for its selection stated?; Q3: Were
variable estimates used in the analysis from the best available source
(i.e., randomized control trial—best, expert opinion—worst)?; Q4: If
estimates came from a subgroup analysis, were the groups prespec-
ified at the beginning of the study?; Q5: Was uncertainty handled by
(1) statistical analysis to address random events, (2) sensitivity
analysis to cover a range of assumptions?; Q6: Was incremental
analysis performed between alternatives for resources and costs?; Q7:
Was the methodology for data abstraction (including the value of
health states and other benefits) stated?; Q8: Did the analytic horizon
allow time for all relevant and important outcomes? Were benefits
and costs that went beyond 1 year discounted (3–5 %) and justifica-
tion given for the discount rate?; Q9: Was the measurement of costs
appropriate and the methodology for the estimation of quantities and
unit costs clearly described?; Q10: Were the primary outcome
measure(s) for the economic evaluation clearly stated and did they
include the major short-term, long-term and negative outcomes
included? Was justification given for the measures/scales used?; Q11:
Were the health outcomes measures/scales valid and reliable? If
previously tested valid and reliable measures were not available, was
justification given for the measures/scales used?; Q12: Were the
economic model (including structure), study methods and analysis,
and the components of the numerator and denominator displayed in a
clear, transparent manner?; Q13: Were the choice of economic model,
main assumptions, and limitations of the study stated and justified?;
Q14: Did the author(s) explicitly discuss direction and magnitude of
potential biases?; Q15: Were the conclusions/recommendations of the
study justified and based on the study results?; Q16: Was there a
statement disclosing the source of funding for the study?
Cost Effectiveness of COPD Treatments 55
estimating the prognosis of an individual patient, it may be
more realistic when considering the effect of disease pro-
gression on a cohort of patients [16]. The probability of
transition between states was often assumed to be constant
over time, and a Markov model does not take into account
previous health states. As such, ‘‘the approach taken did
not account for the existing correlation between the number
of exacerbations in the previous year and the current year
or change in lung function when therapy is withdrawn’’
[18]. Notably, one study used a linked-equations model
[32] and one used a patient-simulation model [31]. The
advantage of these models is that they are not memoryless
(a common feature of Markov models) and can take a
multifactorial and more individualized approach (beyond
lung function) to model disease progression.
A limitation of most of the included studies is that they
did not describe the inclusion of comorbidities (Supple-
mentary Appendix Table A3), with only five of the 18
studies clearly stating which comorbidities were present
[17, 20, 21, 28, 32].
Another limitation reported in multiple studies was that
clinical, healthcare utilization and productivity data were
obtained from patients in countries other than the country
of interest to the CEA [29]. Lastly, many analyses were
based on data from randomized controlled trials (RCT) and
not on real-world evidence [17, 20, 30].
3.3.4 Stated Conclusions and Disclosures
Most studies reported that their intervention was cost
effective; however, in our view, this was not always jus-
tified by the results (QHES item 15). Some studies did not
use an appropriate population [27], correct effectiveness
data [29] or correct comparators [28, 31]. All but two
studies [27, 28] were funded by the pharmaceutical com-
pany that produced the maintenance treatment studied, and
this was clearly stated (QHES item 16). However, the
influence of the funder was not always clear, although the
choice of comparator in the economic evaluation was
obviously largely driven by the choice of comparator in the
clinical studies. Likewise, for the choice of patient popu-
lation. Another issue regarding the funding is that results of
industry-funded studies that indicate unfavourable cost




This review identified that 18 new pharmacoeconomic
analyses of pharmacologic COPD maintenance treatments
have been published in recent years (2011–2015). Most
papers studied the cost effectiveness of LAMA
monotherapy (n = 6), followed by PDE-4 inhibitors
(n = 4) and LABA/ICS combination therapy (n = 4). Two
papers studied both LABA monotherapy and LABA/
LAMA combination therapy. Most studies were cost-utility
analyses, and a minority (39 %) included a more COPD-
specific outcome such as cost per exacerbation avoided. All
studies found the studied therapy to be cost effective or
cost saving, either because of lower treatment costs and the
same effect or because of better effectiveness. However,
QALY gains were small (\0.5 QALYs), and several
methodological shortcomings were identified that ham-
pered firm conclusions regarding the evidence of cost
effectiveness of some of the new treatments.
Medication tended to be more cost effective in more
severely ill populations, that is, those with a high exacer-
bation and hospitalisation risk. Model study results were
also sensitive to assumptions on mortality. Indeed, clinical
trial evidence showed a reduction in exacerbations. How-
ever, no empirical evidence in clinical studies confirmed
that COPD treatments could reduce mortality [1]. Mortality
reductions, as well as changes in health status, were mainly
the indirect result of long-term extrapolation of a relatively
minor improvement in lung function in the first
3–6 months. This suggests that studies have been overly
optimistic.
Notably, all but two studies were funded by the manu-
facturer of the drug that was assessed. The quality of the
studies according to the QHES was generally sufficient,
except for the reporting of potential bias, which scored
consistently low across all studies. However, we identified
several other key methodological issues not included in the
QHES. These included the wide variety of time horizons
(3 months to lifetime), outcomes included (general vs.
COPD specific), the sometimes random combination of
different data sources, inappropriate choice of population
or comparator, calculation of QALYs (either direct via the
EQ-5D or using a mapping model) and, arguably most
importantly, the issue of clinical efficacy versus real-life
effectiveness.
4.2 Detailed Discussion of Methods and Outcomes
4.2.1 Study Design
The vast majority of studies combined clinical trial efficacy
data with long-term follow-up using a Markov model. The
latest approaches, used in the LABA/LAMA evaluations,
used a linked-equation model [32] and a patient-level
simulation model [31]. These models have the potential to
overcome the common Markov limitation of memoryless-
ness and take a multifactorial approach in the modelling of
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disease progression. Yet, only the linked-equation model
seemed to take into account most relevant co-variables
[32], whereas the patient-level model was still mainly
driven by lung function and did not take into account
exacerbation history and other patient-level characteristics
[31]. The authors of the previous review noticed that the
ICER in model studies was often higher than in trial-based
studies [7]. We cannot update this conclusion because of
the small proportion of trial-based studies in this review.
Although another recommendation was to perform sub-
group analyses, this was not always done and was one of
the issues that was poorly defined upfront according to our
QHES assessment. The choice of comparator was often in
line with one of the recommended choices of treatment as
per GOLD guidelines, with some notable exceptions
[27, 31]. Treatment recommendations in the GOLD
guidelines are based on disease severity stages and includes
multiple treatment combinations. Therefore, the design of
many studies does not always match the decisions that need
to be made in real life. In everyday clinical practice, the
question is often whether or not to switch medication,
improve adherence, change the dose or add another med-
ication in patients who remain symptomatic despite the
first-line treatment. However, thus far, these strategies are
mainly understudied, except for one study on the cost
effectiveness of adherence enhancement [36]. Some of
these types of questions have been addressed in the field of
asthma recently [37].
4.2.2 Time Horizon
Studies used a range of different time horizons, varying
between 3 months and lifetime. This may be because
many pharmacoeconomic guidelines do not clearly
define a recommended timeframe for each disease. The
lifetime horizon has been questioned as it cannot take
into account future treatment and price changes [7]. In
general, for more effective treatments, the longer the
time horizon, the higher the potential absolute reduction
in exacerbations and mortality and the higher the costs
and number of QALYs gained. The previous review
argued that a time horizon of 4–5 years may be con-
sidered suitable, in line with the planning cycle of policy
makers [7]. Two studies had time horizons of \1 year
[27, 30]. A 3-month time horizon will likely not include
all relevant health benefits and costs, and a time horizon
shorter than 1 year could lead to an over- or underesti-
mation of results, at least in studies performed alongside
a clinical trial or studies using observational data from
routine clinical or claims databases. For example, in
winter, exacerbation rates and therefore potential gains
are higher [35], but these results cannot be linearly
extrapolated to the full year. When clinical trial efficacy
data are used, the trial should be of sufficient length.
Given the chronic nature, relatively slow progression and
seasonal variability of COPD, the time horizon of CEAs
should be at least 1 year to allow fair comparisons and
to be of value to health insurance companies. Generally,
time horizons should be chosen in such a way that all
expected costs and effects are captured.
4.2.3 Variations in Modelling Approach
Of the 18 studies included, 15 were modelling studies.
The previous review called for the use of similarly
structured Markov models, the inclusion of extra-pul-
monary manifestations (such as comorbidities and exer-
cise) and a shift towards individual patient-simulation
models [7]. Indeed, two of the most recent studies moved
away from the Markov model and used a linked-equations
model [32] or a patient-simulation model [31]. These
models may suffer less from the common Markov limi-
tation but are still based on populations and efficacy data
from clinical trials that may not be fully representative of
real-life medication use. The development of additional
models using longitudinal real-life observational effec-
tiveness data is still necessary. The impact of comorbidity
should thereby at least be considered; only a few studies
incorporated comorbidity. Another issue that must be
taken into account in comparing COPD CEAs is that the
difference in outcomes can be caused by the difference in
the model and the purpose of the model. Hoogendoorn
et al. [38] compared seven different COPD cost-effec-
tiveness models in which the input parameters were
standardized over a 5-year or lifetime time horizon. The
way in which mortality was modelled was the most
determining factor in the difference in outcomes, as well
as the different outcome definitions in models. After
standardization of input parameters, the studied outcomes
still differed: percentage of patients per severity stage,
mortality, QALYs, costs and ICER [38]. Therefore, model
validation may be considered important in COPD models.
Some of the studies included in this review did indeed
validate their models, usually by comparing the model
results with results of other studies [15], the original RCT
[16], real-life data or national statistics [20, 21]. Com-
paring results with those from the original trial may
ensure internal validity, but it does not guarantee the
results can be extrapolated to real-life populations. In
some studies, models were reviewed by an external
source/health economist to improve validation. No struc-
tured validation tools, such as AdViSHE (Assessment of
the Validation Status of Health-Economic decision mod-
els) [39], were used. Model validation may help to
describe whether or not the model realistically describes
the population and disease for which it is intended.
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4.2.4 Variation in Outcomes
As the previous review also found, the outcomes used
varied [7]. QALYs were mostly included, but including
QALYs as the sole outcome can be questionable. QALY
gains were small in most studies, which could mean either
that the effects of the treatments are indeed small or that
the instrument used to measure utility is not sensitive
enough. The finding regarding the small QALY gains also
confirms a finding of the previous review, which high-
lighted the relative insensitivity to change of utility mea-
sures compared with disease-specific health-related quality
of life (HR-QoL) measures in COPD [7]. Another expla-
nation lies in the timing of HR-QoL measurement, which
usually takes place at fixed points in time in trials (e.g. after
3 months, 6 months, 1 year). Thus, utility decrement
because of an exacerbation that occurs between those fixed
timepoints is not always captured [7]. In general, using a
mapping model to translate SGRQ scores into QALYs
resulted in slightly higher QALY gains than direct utility
estimates obtained via the EQ-5D, but this was done in
only two studies, which also included the impact of
comorbidities [14, 32]. The EQ-5D is the questionnaire
most frequently used to estimate utility across all patient
populations. The SGRQ is specifically designed for
patients with respiratory diseases and includes all impor-
tant factors that influence quality of life in patients with
COPD. A recent study mapped the COPD-specific Clinical
COPD Questionnaire (CCQ) [40] to the EQ-5D and found
only moderate correlation [41]. The explanation for this
discrepancy is that the EQ-5D lacks a dyspnoea domain
(one of the most prominent symptoms of COPD) and
includes a pain domain that the CCQ does not as it is a
much less prominent symptom of COPD. Therefore, given
the lack of overlap of important domains, mapping the
CCQ to the EQ-5D cannot be recommended. Note that,
until now, only the EQ-5D-3L has been available, whereas
the EQ-5D-5L has recently been developed. Nolan et al.
[42] studied the responsiveness of the EQ-5D-5L in
patients with COPD and found it was more valid and
sensitive to HR-QoL changes than was the EQ-5D-3L,
which was used in the studies included in this review. The
development of a respiratory ‘bolt-on’ to the EQ-5D may
be another noteworthy future option [43]. In our view, for
comparison between COPD and other diseases, a generic
outcome (such as the QALY) remains essential; however,
we recommend that future research also includes a COPD-
specific measure (such as the CCQ) to fully capture all
relevant COPD-specific outcomes. More studies are needed
to establish clinically relevant cut-offs and the WTP for
these COPD-specific outcomes (e.g. cost per point
improvement in CCQ score or costs per additional patient
with a clinically relevant improvement in CCQ).
The number of exacerbations or change in exacerbation
rate was a frequently used outcome. Together with quality
of life, exacerbations are one of the most important out-
comes as, according to the GOLD guidelines, improvement
of quality of life and reduction in exacerbations are the two
major treatment aims of COPD [1]. GOLD 2015 states that
‘‘Exacerbations and comorbidities contribute to the overall
severity in individual patients’’ and ‘‘It is increasingly
recognized that many patients with COPD have comor-
bidities that have a major impact on quality of life and
survival’’ [44]. Indeed, whereas exacerbations were fre-
quently included, comorbidities were rarely included. We
recommend that comorbidities be included in future
research—particularly when treatment effects are expected
to go beyond COPD only or when comorbidities affect
treatment effectiveness—because they have a considerable
effect on quality of life, economic impact [45] and overall
survival. Furthermore, two papers included pneumonia risk
as an outcome. Hwang et al. [46] studied pneumonia as a
risk factor for exacerbations and found that patients who
had pneumonia in the year before the year of analysis had
an 18 times greater chance of having an exacerbation in the
next year. This outcome should especially be considered
for drugs (such as ICS) that may increase the risk of
pneumonia [47]. The inclusion of other short- and long-
term side effects [48, 49] of pharmacological treatments in
COPD cost-effectiveness models is an area that can be
improved.
4.2.5 Variation in Costs
In line with the previous review, most studies focused on
direct healthcare costs and only included COPD-related
costs [7]. Exacerbations were a primary cost driver but
costs did vary between studies. Differences in exacerbation
costs between countries are expected because of differ-
ences in treatment patterns and healthcare systems. How-
ever, there was also a small difference in exacerbation
costs between studies performed in the same country that
were not due to a difference in calendar year (e.g. Ger-
many), offering some potential for improvement
[17, 20, 22]. However, we should acknowledge that a one-
size-fits-all approach is not always possible because of the
large variation in treatment costs among healthcare insti-
tutions and individual patients with COPD.
4.2.6 Variation in Analytical Approach
All but one study included some kind of sensitivity anal-
ysis, a trend that was observed in the previous review [7].
The majority performed both univariate analysis (1-way)
and PSA. However, one study only performed a PSA [32]
and two studies only performed 1-way analyses [22, 29].
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We recommend both types of analyses be performed as
they provide different information (i.e. what are the cost
drivers and what is the probability of making a correct
overall decision).
Most articles took a payer perspective, two chose a
societal perspective and some included both. All articles
followed their local guidelines for the choice of perspec-
tive. Although we do not aim to undermine local guideli-
nes, we argue that the societal perspective is often of added
value over the healthcare or payer perspective as it
encompasses all costs of an intervention, regardless of who
bears them. All perspectives have their particular rele-
vance. The healthcare perspective is limited to costs within
the healthcare sector, whereas the payer perspective focu-
ses on the money actually paid and may or may not reflect
the actual costs of the resources used. It has been argued
that differences between the healthcare and societal per-
spectives are marginal in COPD because the average age of
patients in many studies is higher than the retirement age,
so the impact of productivity losses would be negligible
[15]. Nevertheless, the societal perspective incorporates
more than just productivity losses. It may also include
informal care, and travel and time costs to patients,
although these are often neglected, unfortunately. Obvi-
ously, if younger working age patients with COPD are
studied, production losses may have a large impact on
study results [50].
4.2.7 Transferability Issues
All but three studies were performed in a European country,
with the majority in the UK, Sweden or Germany. Three
studies were conducted outside Europe: the first, by the
World Health Organization, reported on the cost effective-
ness of COPD medication in sub-Saharan Africa and south-
east Asia [28]; the second was performed in the USA [19];
and the third in India (Tables 1, 2, 3, 4, 5) [27]. Most
countries used cost and effectiveness data from the same
country, with the notable exception of Roggeri et al. [29],
who applied Italian cost data to Swedish effectiveness data.
4.2.8 Other Issues: Efficacy versus Effectiveness
An important issue not covered by the QHES is whether
the cost effectiveness is representative of the real-life
population that will eventually use the particular drug.
Most papers focused on moderate to very severe COPD
(GOLD 2–4) or even only on severe and very severe COPD
(GOLD 3–4). Indeed, in GOLD 1 COPD, only short-acting
bronchodilators are recommended. The new GOLD A–D
classification was seldom used to describe the patient
population. In the new GOLD guidelines, clinical mani-
festations such as the exacerbation history or the extent of
chronic bronchitis play a more prominent role in the
selection of treatment. Very few studies incorporated this
new focus [27, 31]. However, note that the new GOLD
guidelines are not particularly modeller friendly, especially
compared with previous guidelines that only considered
FEV1, which enabled progression predictions.
Another important issue identified was efficacy versus
effectiveness. Most studies included in this review used
clinical trial efficacy data in their models. However, clin-
ical trial populations do not fully represent real-life popu-
lations [51]. The majority of large clinical COPD trials
only include patients with significant smoking history ([10
pack years), an FEV1 \70 % and no atopy or asthma
comorbidity [51]. However, in real life, about 22 % of
patients with COPD are never smokers and 15 % of
patients also have asthma [52]. As a result, less than half of
the real-life primary care COPD population (42 %) [53]
would be eligible to participate in the UPLIFT trial that
was frequently used as basis for CEAs of tiotropium
[54, 55]. Moreover, efficacy as seen in controlled settings
differs from effectiveness during use in daily practice [56].
For example, in contrast to the well-trained patients in
clinical trials, real-life patients often have poor inhalation
technique and adherence, which is associated with worse
health outcomes [57, 58]. This might be of interest with
regard to the recent developments towards more conve-
nient dosing regimens and innovative inhalers. In clinical
trials, inhaler efficacy has been shown to be comparable
[59], resulting in small differences in incremental cost
effectiveness based on trial data. However, differences may
be revealed in real-life studies [60].
Lastly, we should acknowledge that some drugs are
prescribed outside their main indication (off-label pre-
scribing). The extent of this phenomenon and cost effec-
tiveness in those groups is unknown.
In general, most studies used data from large pharma-
ceutical industry-sponsored RCTs as the basis for their
economic evaluations. This might be a suitable approach
for a first indication of cost effectiveness, as no long-term
real-world data are available at that stage. After C1 year of
experience in real life, follow-up studies using data from
routine clinical or claims databases may be of added value
to assess the cost effectiveness during use in daily practice.
However, these studies have their own limitations and
challenges, such as dealing with bias, a large level of
missing data and potentially incorrect diagnoses.
4.3 General Recommendations
The main conclusions and recommendations of the previ-
ous review [7] were as follows: perform longer trial-based
studies, assess combinations of medication, assess treat-
ment strategies, include a greater diversity of COPD
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populations, reach consensus on a common structure of
COPD models, and use standardized COPD outcomes
(such as exacerbations) and their minimal clinically
important differences and WTP, in addition to the cost per
QALY. The majority of these recommendations are still
valid, but we identified some new issues, such as the
incorporation of real-life evidence and the need for post-
marketing CEAs and the need for COPD-specific
methodology and outcomes. In the last decade, we have
seen a shift from economic evaluation alongside RCTs to
longer-term Markov modelling to individualized mod-
elling. The next step is to validate these models using
longitudinal real-world routine practice data. Table 6 pre-
sents an overview of our main recommendations from this
review.
4.4 Strengths and Limitations
This systematic review has several strengths, including
adhering to PRISMA guidelines, searching four major
databases and the consistency and interaction with a
previous review that included all previous COPD CEAs.
However, the study also has some limitations, the first
being that we only included articles in Dutch, English and
German. Although this included the vast majority of the
articles published, and non-English articles are usually of
limited added value [61], it may be considered a possible
source of bias. We used the QHES score to systematically
assess the quality of the studies included. However, as this
checklist and its score are open for interpretation and dis-
cussion, results should be interpreted with caution. The
QHES checklist asks whether a certain part is performed;
however, this does not directly resemble the quality of how
it is done. This is also a common limitation of other
quality-assessment tools, such as CHEERS [12]. Therefore,
we also performed additional detailed assessments, focus-
ing on COPD-specific issues and following the recom-
mendations of the previous review. This study should
therefore be interpreted as ‘topping up’ the previous work.
This means that, where these additions are treated as a
continuum in these interpretations technically represents a
disjoint with the search criteria in 2011.
Table 6 Key recommendations for future chronic obstructive pulmonary disease cost-effectiveness analyses and gaps in research
Recommendations for cost-effectiveness analyses of COPD treatments
Time horizon
Time horizon chosen should capture all relevant costs and effects and should reflect the chronic, progressive nature of COPD and its
seasonal variability
The optimal time horizon depends on the outcomes. Preferably, include multiple time horizons, including policy-relevant time horizons of
4–5 years and lifetime
Population
The patients included should be patients for whom the therapy is indicated and should be representative of the broad real-life population
Comparator
The comparator should be usual care as seen in daily clinical practice
Costs
Use data sources from the same country and where possible standardize unit costs within a country
Minimum costs to include are medication costs and hospitalization costs
Outcomes
Distinguish between severe exacerbations (requiring hospitalization) and non-severe exacerbations (requiring GP/ED/specialist visit and
short-course oral corticosteroids with or without antibiotics)
Incorporate separate utility estimates for stable periods and for during exacerbations
Ideally, include both a generic outcome (e.g. QALY) and a COPD-specific outcome
Model validation
If models are used, both internal and external validation is recommended. Preferably, use a standardized model validation tool
Gaps in cost-effectiveness analyses of COPD treatments
Incorporate comorbidity, when relevant
Incorporate adherence, when relevant
Incorporate side effects, when relevant
Validate long-term model outcomes using longitudinal real-life data
Cost effectiveness of treatment strategies as seen in real life (e.g. step-up or dose increase)
Establish MCID and WTP for COPD-specific outcomes
COPD chronic obstructive pulmonary disease, ED emergency department, GP general practitioner, MCID minimal clinically important dif-
ference, QALYs quality-adjusted life-years, WTP willingness to pay
60 S. van der Schans et al.
5 Conclusions
The majority of CEAs conducted between 2011 and 2015
indicated the cost effectiveness of pharmacologic mainte-
nance treatments for COPD was favourable. However, the
number of QALYs gained was generally small. According
to the QHES, the quality of the studies was generally
sufficient, but studies poorly reflected cost effectiveness in
real life. Therefore, in addition to modelling approaches to
assess initial cost effectiveness, further studies using data
from daily clinical practice seem valuable to assess real-
world cost effectiveness.
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